These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9707267)

  • 1. Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease.
    Mancini GB
    Am J Med; 1998 Jul; 105(1A):40S-47S. PubMed ID: 9707267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging concepts: angiotensin-converting enzyme inhibition in coronary artery disease.
    Mancini GB
    Cardiovasc Drugs Ther; 1996 Nov; 10 Suppl 2():609-12. PubMed ID: 9115953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-ischemic effects of angiotensin-converting enzyme inhibitors: a future therapeutic perspective.
    Ambrosioni E; Bacchelli S; Esposti DD; Borghi C
    J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S3-9. PubMed ID: 11392476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure.
    Hornig B; Arakawa N; Drexler H
    Eur Heart J; 1998 Jul; 19 Suppl G():G48-53. PubMed ID: 9717056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study.
    Mancini GB; Henry GC; Macaya C; O'Neill BJ; Pucillo AL; Carere RG; Wargovich TJ; Mudra H; Lüscher TF; Klibaner MI; Haber HE; Uprichard AC; Pepine CJ; Pitt B
    Circulation; 1996 Aug; 94(3):258-65. PubMed ID: 8759064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial function and bradykinin in humans.
    Hornig B; Drexler H
    Drugs; 1997; 54 Suppl 5():42-7. PubMed ID: 9429844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR; Noll G; Lüscher TP
    Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium.
    Ferrari R; Guardigli G; Ceconi C
    Cardiovasc Drugs Ther; 2010 Aug; 24(4):331-9. PubMed ID: 20577898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide.
    Mombouli JV
    Drugs; 1997; 54 Suppl 5():12-22. PubMed ID: 9429841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibitors and coronary artery disease.
    Sayer JW; Timmis AD
    Cardiovasc Drugs Ther; 1996 Nov; 10 Suppl 2():631-7. PubMed ID: 9115957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating atherosclerosis through inhibition or blockade of angiotensin.
    Rosenson RS
    Clin Cardiol; 2003 Jul; 26(7):305-11. PubMed ID: 12862295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease?
    Ruschitzka FT; Lüscher TF
    Am Heart J; 1997 Aug; 134(2 Pt 2):S31-47. PubMed ID: 9313622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronary endothelial vasodilator dysfunction: clinical relevance and therapeutic implications.
    Zeiher AM; Schächinger V
    Z Kardiol; 1994; 83 Suppl 4():7-14. PubMed ID: 7856284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story.
    Ferrari R; Fox K
    Drugs; 2009; 69(3):265-77. PubMed ID: 19275271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of cardiac function by angiotensin converting enzyme inhibition. Sites of action.
    Dietz R; Waas W; Süsselbeck T; Willenbrock R; Osterziel KJ
    Circulation; 1993 May; 87(5 Suppl):IV108-16. PubMed ID: 8485825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Endothelial dysfunction and angiotensin-converting enzyme inhibitors in coronary disease].
    Mélon P
    Rev Med Liege; 1998 Jun; 53(6):353-4. PubMed ID: 9713215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?
    Remme WJ
    Drugs; 1997; 54 Suppl 5():59-70. PubMed ID: 9429846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The endothelium in acute coronary syndromes.
    Noll G; Lüscher TF
    Eur Heart J; 1998 Apr; 19 Suppl C():C30-8. PubMed ID: 9597423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection.
    Parmley WW
    Am J Med; 1998 Jul; 105(1A):27S-31S. PubMed ID: 9707265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular protection: current possibilities and future perspectives.
    Lüscher TF
    Int J Clin Pract Suppl; 2001 Jan; (117):3-6. PubMed ID: 11715356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.